There has been a transformational change in understanding heart failure due to transthyretin cardiac amyloidosis (ATTR-CA). Previously considered a rare condition, the widespread adaptation of nuclear imaging to establish the diagnosis has led to the recognition that ATTR-CA is commonly encountered in clinical practice. Additionally, the advent of effective disease-modifying therapies that reduce morbidity and mortality among affected patients has afforded hope to those newly diagnosed. Because these disease-modifying therapies are more effective when administered early in the course of the illness, before significant end-organ dysfunction has occurred, it is vital to facilitate early diagnosis.
